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Background: Indacaterol/glycopyrronium (IND/GLY) is a once-daily inhaled fixed-dose combi-
nation of indacaterol (IND), a long-acting b2-adrenergic agonist (LABA), and glycopyrronium
(GLY), a long-acting muscarinic antagonist (LAMA) for use as maintenance treatment to relieve
symptoms of chronic obstructive pulmonary disease (COPD) in adults.
Objective: To determine the economic benefits of IND/GLY compared with the free combina-
tion of indacaterol and glycopyrronium (IND þ GLY), and with the fixed-dose combination of
salmeterol/fluticasone (SFC), in a moderate-to-severe COPD population with low-
exacerbation risk. The model-based analysis extrapolated results up to lifetime time horizon
and calculated costs per quality-adjusted life year.
Methods: Assuming equal efficacy, a cost-minimisation analysis compared IND/GLY vs
IND þ GLY using model inputs from the double-blind, randomised SHINE trial. The double-
blind, randomised ILLUMINATE and TORCH trials were used to analyse cost-effectiveness versus
SFC. To consider ICS-related pneumonia events, published odds ratio comparing an ICS-
exposed group to a control group of COPD patients was used. Direct and indirect drug costs
as well as drug acquisition costs (in Swedish Krona [SEK]) were derived from published Swedish7323200.
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Swedish cost-effectiveness analysis of indacaterol/glycopyrronium 1787sources. Cost and effects were discounted with 3%. Uncertainty was assessed by one-way and
probabilistic sensitivity analyses (PSA).
Results: IND/GLY was cost-saving vs IND þ GLY with incremental savings of SEK (EUR) 768 (85),
and 3309 (368) per patient over one and five years. IND/GLY was found to be less costly and
more effective compared to SFC with cost savings of SEK (EUR) 2744 (303), 8854 (976),
13,938 (1536), 27,495 (3031) and 43,033 (4744) over one, three, five, ten years and lifetime.
The PSA indicated that all iterations produced dominant results for IND/GLY.
Conclusion: IND/GLY is cost-minimising vs INDþGLYanddominates SFC in themaintenance treat-
ment ofCOPDpatients in Sweden.Encouragingdual bronchodilator therapyoveran ICS-containing
combination results in lower total costs and better outcomes compared to combination therapy
including fluticasone in moderate-to-severe COPD patients with low exacerbation risk.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a pro-
gressive and treatable but incurable disease, found to be a
major cause of chronic morbidity and mortality worldwide
[1]. Studies consistently report COPD to be a leading cause
of death [2,3]. In Sweden the prevalence of COPD, defined
according to the Global Initiative for Chronic Obstructive
Pulmonary Disease (GOLD) guidelines, was estimated to be
14.1% of the adult population aged 20e69 [4]. Population
studies have shown that COPD is largely underdiagnosed [4]
or misdiagnosed as asthma [5,6], and of those diagnosed
many remain undertreated [7].
The economic burden of COPD in Sweden was estimated
at SEK 13.9 billion (EUR 1.46 billion) in 2010 with the ma-
jority of costs found to be attributable to indirect costs due
to loss of productivity. Main drivers of the direct costs were
hospitalisations (for the very severe patients), and drug
costs (for the patients with severe, mild or moderate dis-
ease) [8]. Improving the management of COPD patients will
allow for greater symptom control and thus likely reduce
loss of productivity as a result of the disease. Additionally,
improved disease management and effectiveness of treat-
ments is likely to reduce COPD related hospitalisations
resulting in cost-savings to the health care system [9].
There are a number of pharmacologic therapy options
for COPD. Long-acting bronchodilators, in the form of long-
acting b2-agonists (LABAs) or long-acting muscarinic
antagonist (LAMAs), are central to the management of
COPD. When symptoms are not adequately controlled by a
single LABA or LAMA, international guidelines recommend
combining bronchodilators from different classes [1]. The
current Swedish guidelines (released in 2009) recommend
LAMA as first-line treatment and LABA as alternative or add-
on treatment for inadequately controlled COPD patients.
For more severe patients with frequent exacerbations,
inhaled corticosteroids (ICS) in combination with LABA are
recommended [10]. However, in 2013 approximately 55% of
the total number of COPD patients over 45 years have been
treated with an ICS/LABA combination, 29% with LAMA and
17% with LABA [11]. The high usage of ICS/LABA has also
been published in a regional assessment report based on
data from the PRAXIS study which showed that 40% of pa-
tients in GOLD states 1 and 2 in Sweden are treated with
ICS/LABA combination [12]. Prescribing of ICS/LABA outsideof the GOLD guidelines has also been reported from real-
world data in other countries [13e18]. However, patients
receiving an inhaled corticosteroid with LABA or in addition
to dual bronchodilator therapy, are at risk for additional
adverse events such as pneumonia and influenza [19].
Non-adherence to the recommendations from clinical
guidelines was found to increase the burden of COPD in
subjects with moderate-to-severe disease [20,21]. The
long-term bronchodilator strategy for COPD patients is
therefore of clinical and economic interest and especially
relevant from a policy and payer perspective.
Indacaterol/glycopyrronium bromide (IND/GLY)
(Ultibro Breezhaler) is a fixed-dose LABA/LAMA combi-
nation which received reimbursement in Sweden in
February 2014 providing a new alternative for patients
remaining symptomatic with long-acting monotherapy [22].
It is a once-daily inhaled fixed-dose combination of inda-
caterol (IND), a LABA, and glycopyrronium bromide (GLY), a
LAMA, and it is indicated as a maintenance bronchodilator
treatment to relieve symptoms in adult patients with COPD
[23]. This fixed-dose LAMA/LABA combination provides a
new alternative for patients remaining symptomatic with
long-acting monotherapy.
The objectives of this study were to compare IND/GLY
with the free combination of indacaterol plus glyco-
pyrronium (IND þ GLY) in terms of costs and to evaluate its
cost-effectiveness versus the fixed-dose combination of
salmeterol/fluticasone (SFC), in moderate to severe COPD
population with a low-exacerbation risk from a Swedish
societal perspective. Although SFC is not recommended for
use in COPD patients with low exacerbation risk [1] it was
included as a comparator as it is often used in such patients
in clinical practice [18]. This cost-effectiveness analysis
aims therefore to provide the longer-term evidence in
terms of quality-adjusted life years (QALYs) and costs of
using IND/GLY combination over SFC in a moderate-to-
severe COPD population with low-exacerbation risk.Methods
Model structure
This was a patient-level simulation model in which Monte
Carlo simulation methods [24] were used to follow individual
Table 1 Population and efficacy inputs for comparison of IND/GLY and the free combination.
IND/GLY IND þ GLYb
Mean Range (SD/95% CIa) Source Mean Range (SD/95% CIa)
COPD severity at baseline, % patients
Moderate 63.6% e [37] 63.6% e
Severe 36.4% e [37] 36.3% e
Age at baseline, years 63.9 SD  8.83 [37] 63.9 SD  8.83
Males at baseline, % 75.4 e [37] 75.4 e
FEV1 improvement vs. placebo at
26 weeks, L
0.2 95% CI: 0.17, 0.24 [37] 0.2 95% CI: 0.17, 0.24
Exacerbation rate versus placebo 0.57 95% CI: 0.41, 0.79 [38] 0.57 95% CI: 0.41, 0.79
a For the calculation of 95%, a standard error was assumed to be 10% of the mean. SDZ standard deviation, CIZ confidence interval.
b Assumption of efficacy and safety equivalence between IND/GLY and IND þ GLY applied.
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patients were moved through the model one at a time, pro-
gressing and experiencing clinical events according to preset
probabilities. Disease severity was determined at each cycle
based on the patient’s lung function. In the event of discon-
tinuation, patients had their FEV1 levels fall back to what it
would have been, had they never been treated. Probabilities
of exacerbation (severe or non-severe) were determined by
severity of disease and treatment choice. Exacerbations were
defined in annual rates which in turn were adjusted to the
specified cycle length. Cycle lengths were 6 months, with
outcomes reported over time horizons of one, three, five and
10 years and over a lifetime. Discounting of 3.0% for costs and
outcomes was applied. The structure of the model was pre-
viously described in detail and validated [25]. The predict-
ability of themodelwas tested bypopulating itwith data from
natural history of disease studies as well as with clinical trial
data. The validation with these studies found the model to
have goodpredictive ability, yielding in thiswaya gooddegree
of external validity.Figure 1 ModeThe model produced three categories of outputs e
clinical, cost and cost-effectiveness. This allowed cost-
minimisation and cost-effectiveness analyses to be con-
ducted. In addition, number needed to treat (NNT) to avoid
one exacerbation and cost per exacerbation avoided can be
calculated on the basis of the clinical and cost-
effectiveness sets of outputs.
Clinical data
Comparison of indacaterol/glycopyrronium with the free
combination
The BEACON study was a phase III study comparing the
safety and efficacy of IND/GLY versus concurrent adminis-
tration of IND þ GLY for a blinded treatment period of 28
days [26]. The primary objective of the study was to eval-
uate the non-inferiority of IND/GLY as compared to the
concurrent administration of IND þ GLY in terms of its ef-
fect on trough FEV1 after 28 days of treatment. A total of
193 patients were randomised, of which 59.6% and 40.4%l schematic.
Table 2 Population and efficacy inputs for comparison of IND/GLY and SFC.
IND/GLY SFC
Mean Range (SD/95% CIa) Source Mean Range (SD/95% CIa) Source
COPD severity at baseline, % patients
Moderate 80.3% e [27] 80.3% e Assumed
Severe 19.7% e [27] 19.7% e Assumed
Age at baseline, years 63.3 SD  7.93 [27] 63.3 SD  7.93 Assumed
Males at baseline, % 70.9 e [27] 70.9 e Assumed
FEV1 improvement vs.
placebo at 26 weeks, L
0.259 95% CI: 0.209, 0.311 [27] [28] 0.159 95% CI: 0.129, 0.191 [28]
Exacerbation rate versus placebo 0.61 95% CI: 0.37, 0.85 Calculated 0.75 95% CI: 0.48, 1.03 Calculated
ICS-related pneumonia risk versus
control group (odds ratio)
1.0 95% CI: 0.9, 1.1 Assumed 1.78 95% CI: 2.62, 3.70 [19]
a For the calculation of 95%, a standard error was assumed to be 10% of the mean. SDZ standard deviation, CIZ confidence interval.
Swedish cost-effectiveness analysis of indacaterol/glycopyrronium 1789had moderate and severe disease, respectively. The BEA-
CON study demonstrated that once-daily IND/GLY provides
an efficacy and safety profile similar to the concurrent
administration of its monocomponents [26]. Given the evi-
dence of non-inferiority between IND/GLY and the free
combination of the components, the first analysis was run
as a cost-minimisation analysis.
The population and efficacy inputs used for the com-
parison of IND/GLY with the free combination of IND þ GLY
are summarised in Table 1.
Comparison of indacaterol/glycopyrronium with
salmeterol/fluticasone
Model inputs for the comparison of IND/GLY versus SFC
were derived on the basis of data from the ILLUMINATE trial
[27]. Since the model described treatment effects versus a
placebo baseline the study of Mahler et al. [25] and the
TORCH trial [24] have been used to estimate input values
compared to placebo.
ILLUMINATE was a 26-week treatment, randomised,
double-blind, multicentre study, with parallel-group and
double dummy design to assess the efficacy, safety and
tolerability of IND/GLY compared to SFC in patients with
moderate (80.3%) and severe (19.7%) COPD. The primary
endpoint was to demonstrate the superiority of IND/GLY
compared with SFC for the standardised area under the
curve from 0 to 12 h post dose for FEV1 after 26 weeks of
treatment [27].
IND/GLY improvement from baseline in FEV1 (L) at 26
weeks was based on data from ILLUMINATE [27] and SFC’s
improvement from Mahler et al. [28]. The model design
required the FEV1 improvement of the therapies to be
estimated compared to a placebo baseline. Such data was,
however, not available from the ILLUMINATE trial [27] due
to the lack of a placebo arm in the study. Thus, data from
Mahler et al. [28] for FEV1 improvement of SFC versus
placebo was used. Reflecting the mean treatment differ-
ence of 0.1 L for IND/GLY versus SFC, the IND/GLY FEV1
improvement was calculated as the treatment effect of
SFC versus placebo plus 0.1 L. Thus, input values for the
model were 0.259 L for IND/GLY and 0.159 L for SFC versus
placebo, as all FEV1 values were benchmarked versus pla-
cebo. Similarly, for the calculation of the exacerbation
rates versus placebo, a placebo arm was needed. TheTORCH trial (which was once again selected in the absence
of a pooled and adjusted source to provide a placebo an-
chor) reported a rate ratio of 0.75 (95%CI: 0.69e0.81) for
SFC versus placebo [29]. This rate ratio of 0.75 was applied
to the annual rate of exacerbations for SFC from ILLUMI-
NATE, 1.05 [30], to derive a hypothetical placebo rate of
1.40; this placebo rate was used with the IND/GLY annual
exacerbation rate (0.847(30)) to derive a rate ratio of IND/
GLY versus placebo. For the consideration of the ICS-
related pneumonia events, published odds ratio
comparing an ICS-exposed group to a control group of COPD
patients was used [19].
A summary of the population and efficacy inputs used for
the comparison of IND/GLY with SFC are summarised in
Table 2.Costs
The analysis was conducted from the societal perspective
and accounted for direct and indirect costs. Direct costs
comprised COPD drugs, maintenance, exacerbation event
and pneumonia event costs. Daily drug costs (in Swedish
Krona [SEK]) were derived from the Swedish National For-
mulary of Drugs [31]. Maintenance cost was defined as non-
exacerbation-related cost, after the exclusion of COPD
drug costs, and was based on two subsequently published
analyses from the OLIN study [8,32]. The published mainte-
nance costs from 2010 [8] were adjusted by the relative
proportion of costs for exacerbations from the earlier pub-
lication using the same data source [8,32]. Costs of exacer-
bation were calculated based on data from a cost-of-illness
study in the Swedish setting [33]. Exacerbations were clas-
sified as non-severe or severe depending on the associated
resource utilisation. A patient with a non-severe exacerba-
tionwas assumed to visit a physician and requiring temporary
additional therapy. An exacerbationwas considered severe if
the patient needed to be admitted to the hospital. The costs
per non-severe and severe exacerbationswere SEK 1,239 and
SEK 26,590, respectively. Pneumonia costs were based on
three diagnosis-related group (DRG) codes (D47A, D47C,
D47E) describing lung inflammation with three varying levels
of complication [34]. As no information on case-mix of these
three different DRGs was available, a straight average of
1790 D. Price et al.these three has been used. Costs included in the analysis are
presented in Table 3.
Mortality
Probability of death was determined by a COPD-specific
mortality hazard ratio [34] and general all-cause mortality.
The Obstructive Lung Disease in Northern Sweden (OLIN)
study was used to describe the risk of death per unit increase
in FEV1%. OLIN was a Swedish longitudinal study that fol-
lowed COPD patients (64% male) over a period of 20 years,
having mortality as a primary endpoint [4]. Swedish life ta-
bles from the Official Statistics of Sweden [35] for 2013 were
used to describe the background all-cause mortality.
Utilities
Baseline utilities were applied at each cycle depending on
the disease severity state of the patient and a number of
other characteristics. These were calculated based on a
regression model published by Rutten van Molken et al.
[36]. This regression function allows utilities to be assigned
to patients based on a multi-factorial consideration, rather
than based solely on the 2008 GOLD disease severity
classification.
The co-efficient values used in the regression model
included gender, post-bronchodilator FEV1% predicted,
number of hospital admissions and emergency visits in the
previous year, body mass index (BMI) and comorbidities.
Utility at each cycle is calculated by the regression
equation as below:
Utility value Z 0.688 þ Gender*0.057 þ FEV1 percent
predicted* 0.003 þ ER visits in the last year þ -
0.029þHospital admission in the last year *0.02þ Number
of concomitant diseases*-0.01 þ BMI*-0.003.Table 3 Cost inputs (in SEK).
Costs (SEK) Source
Direct costs
Daily drug cost
IND/GLY 19.31 [31]
IND þ GLY 21.46 [31]
SFC 19.69 [31]
Annual cost of maintenancea
GOLD 1 e
GOLD 2 e
GOLD 3 12,995 [8,32]
GOLD 4 43,469 [8,32]
Cost per exacerbationa
Non-severe 1239 [8,32]
Severe 26,590 [8,32]
Cost per pneumonia episode 42,169 [39]
Annual indirect costsa
GOLD 1 3133 [8]
GOLD 2 21,877 [8]
GOLD 3 34,407 [8]
GOLD 4 118,517 [8]
a Inflated with consumer price index to 2013.Uncertainty
One-way sensitivity analysis (OWSA) and probabilistic
sensitivity analysis (PSA) were performed for the cost-
effectiveness comparison to account for uncertainty in
the model. The effects of individual variables were esti-
mated in the OWSA, by testing an upper and lower limit.
Key model inputs varied were FEV1 improvement, exacer-
bation rate versus placebo, and severity of population at
baseline. To account for second order uncertainty, a PSA
was conducted for 1000 cohorts with 10,000 patients per
cohort.
Results
Comparison of indacaterol/glycopyrronium with
the free combination
IND/GLY resulted in incremental cost savings versus the
free combination, ranging from SEK -768 and SEK -8703
depending on the time horizon. The results of the cost-
minimisation analysis are presented in Table 4.
Comparison of indacaterol/glycopyrronium with
salmeterol/fluticasone
IND/GLY was dominant for all time horizons versus SFC,
meaning the total estimated costs were lower and resulted
in better outcomes. Cost savings occurred for drug, main-
tenance, exacerbation, pneumonia event and indirect
costs. Most of the savings were due to reduction in the in-
direct and maintenance costs. Patients receiving IND/GLY
had no pneumonia events, less severe and non-severe ex-
acerbations and better outcomes in terms of number of life
years (LYs) and QALYs. Numbers needed to treat to avoid
one exacerbation ranged from seven over one year to one
over five and ten years and 0.42 over a lifetime (Table 5).
Uncertainty
Results from the OWSA suggested that the FEV1 improve-
ment and the disease severity of the patients included in
the analysis would have the highest impact on the esti-
mates. The PSA found IND/GLY to be dominant in allTable 4 Results of the base case cost-minimisation anal-
ysis (IND/GLY vs IND þ GLY).
Time horizon
(years)
Total costsa (SEK) Incremental
total costs
(SEK)
IND/GLY IND þ GLY
1 27,635 28,403 768
3 91,788 93,906 2118
5 149,464 152,772 3309
10 273,053 278,685 5632
Lifetime 500,248 508,951 8703
a Total costs Z direct costs (drug, maintenance [additional
therapy], exacerbation, pneumonia-related costs) and indirect
costs.
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basis of the PSA is presented in Fig. 2 below.Figure 2 Results of probabilistic sensitivity analysis: incre-
mental cost-effectiveness scatter plot of IND/GLY versus SFC.Discussion
To the authors knowledge this analysis is the first to explore
the comparisons of a fixed combination of LABA/LAMA with
a free LABA þ LAMA combination or SFC. The results of the
cost-minimisation analysis versus the free combination of
IND þ GLY suggested that IND/GLY was associated with in-
cremental cost savings over one, three, five and 10 years as
well as over the lifetime at a daily cost of SEK 19.31. IND/
GLY was found to dominate SFC at all time horizons. IND/
GLY was associated with cost savings, and efficacy and
safety benefits when compared with SFC.
The conducted analyses had several limitations. The
cost-minimisation comparison of IND/GLY versus the free
combination was based on the assumption of non-
inferiority. This implied that compliance and effective-
ness were assumed to be equivalent between the two
comparators. The main limitation of the cost-effectiveness
analysis was the lack of direct evidence that can be used for
the comparison versus SFC in terms of therapy FEV1
improvement against placebo and therapy exacerbation
benefit versus placebo. The current analysis is based on the
assumption that the baseline rates for placebo from one
trial can be used in another.
A further limitation of the analyses is that formoterol/
budesonide (FBD) could not be included in this analysis. FBD
is the more widely used LABA/ICS product in Sweden, and
there is also differential evidence for ICS-related adverse
events when using fluticasone or budesonide. The compari-
son of IND/GLY versus SFC may therefore not be general-
isable to a comparison versus FBD. However, no head-to-
head clinical data was available to support this comparison.
The analyses were conducted according to the 2008
GOLD Guidelines Update COPD disease severity classifica-
tion based on FEV1 to reflect the approach followed in the
clinical trials used as the source for the clinical inputs. One
area of new research could be to explore the impact of the
GOLD 2011 guidelines classification which has been rede-
fined using exacerbation history and symptoms in addition
to spirometry. This would result in different classifications
of disease severity and potentially allow evaluation of drug
therapies tailored to more specific groups of patients.
In the current COPD treatment paradigm, dual bron-
chodilator therapy is recommended; however, as no fixed-Table 5 Incremental results of the base case cost-effectivenes
Time horizon
1 year 3 years
Incremental costs (SEK) 2744 8854
Direct costs 1156 3709
Indirect costs 1588 5145
Incremental life-years 0 0.00
Incremental QALYs 0.001 0.00
Incremental pneumonia events 0.02 0.06
Exacerbations avoided 0.06 0.22dose dual bronchodilator was previously available, this
provides a new treatment option for moderate-to-severe
COPD patients without the potential risks of ICS. This
analysis explores the potential consequences of encour-
aging a dual bronchodilator therapy over a combination
with ICS and showed that non-ICS therapy results in less
pneumonia events, severe and non-severe exacerbations
and better outcomes compared to combination therapy
including fluticasone in moderate-to-severe COPD patients.
Payers and policy-makers should be encouraged to ensure
that guidelines are followed and tested before resorting to
the addition of an ICS. Compliance with clinical guidelines
will result in both cost-savings for the system as well as
improved health outcomes in patients with moderate-to-
severe COPD and low exacerbation risk.
Sweden is currently reviewing the price of respiratory
drugs that may impact on the results of the analysis con-
ducted here by lowering the price of SFC. While the
magnitude of the exact price reduction is unknown, the
current parameters indicate that an approximately 20%
reduction in SFC would still result in IND/GLY dominating
SFC. However, in that scenario cost-savings are smaller
especially in the shorter time horizons. While these dif-
ferences are small on a per patient basis, they may provide
significant savings for health care systems managing large
populations. When the price reduction reaches 25%, one-
year time horizon results are no longer dominant, and when
larger price reductions are applied the ICERS has to be
evaluated based on Swedish cost-effectiveness thresholds.
In conclusion, the conducted analyses found IND/GLY to
be costesaving when compared with the free combination
of IND þ GLY and cost-effective when compared with SFC,
in patients with moderate or severe COPD and lows analysis for IND/GLY versus SFC.
5 years 10 years Lifetime
13,938 27,495 43,033
5883 11,495 18,157
8055 15,999 24,876
5 0.015 0.063 0.310
6 0.015 0.047 0.200
0.10 0.18 0.31
0.37 0.68 1.07
1792 D. Price et al.exacerbation risk. The results imply that the use of IND/GLY
is likely to reduce the economic burden of the disease to
the Swedish healthcare system. Results are likely to be true
in other markets in terms of cost-savings generated by
avoidance of clinical events; the overall cost-effectiveness
results will be dependent on drug prices, but the results
from Sweden indicate that an approximately 20% price
differential between IND/GLY and SFC would still result in
overall cost-savings.Conflict of interest
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